Alpha Tau Medical公布了其在美国进行的Alpha Dart®治疗复发性胶质母细胞瘤试验的突破性中期结果。数据显示,该疗法实现了100%的局部疾病控制率,以及67%的完全缓解率,同时展现出良好的安全性特征。
公司已安排于美东时间上午8:30举行电话会议,进一步讨论这些令人瞩目的中期数据。
Alpha Tau Medical公布了其在美国进行的Alpha Dart®治疗复发性胶质母细胞瘤试验的突破性中期结果。数据显示,该疗法实现了100%的局部疾病控制率,以及67%的完全缓解率,同时展现出良好的安全性特征。
公司已安排于美东时间上午8:30举行电话会议,进一步讨论这些令人瞩目的中期数据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.